Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Authors
Ford, HMarshall, A
Bridgewater, J
Janowitz, T
Coxon, F
Wadsley, J
Mansoor, Was
Fyfe, D
Madhusudan, S
Middleton, G
Swinson, D
Falk, S
Chau, I
Cunningham, D
Kareclas, P
Cook, N
Blazeby, J
Dunn, J
Issue Date
2014-01
Metadata
Show full item recordAbstract
Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to active symptom control alone can improve survival and HRQoL for patients.Citation
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. 2014, 15 (1):78-86 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(13)70549-7PubMed ID
24332238Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(13)70549-7